JPMorgan analyst Brian Cheng initiates coverage on Dianthus Therapeutics (NASDAQ: DNTH) with a Overweight rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage